Dr Scott Gottlieb says people with covid won’t be immune forever

Dr Scott Gottlieb says people with covid won't be immune forever

People who have been previously infected with COVID should eventually get vaccinated against the disease, as their immune defenses will weaken over time, Dr Scott Gottlieb told CNBC on Wednesday.

The former Food and Drug Administration commissioner on “Squawk Box” said, “The immunity conferred by natural infection appears strong and appears to be long-lasting. We know it lasts at least six months, maybe longer.

“I guess it won’t last forever. At some point, these people will need to be vaccinated, ”said Gottlieb, who now sits on the board of directors of vaccine maker Pfizer.

An important question about natural immunity is whether a case of COVID more severe than a person who has remained asymptomatic, for example, leads to better protection.

“With SARS and MERS, we saw that people who got sicker had longer lasting immunity. We don’t know if that’s the case with this SARS-CoV-2 virus, but it could happen, ”Gottlieb said. In reference to. Other types of coronavirus – severe acute respiratory syndrome and Middle East respiratory syndrome – have led to epidemics in many countries.

According to the World Health Organization, SARS was first detected in 2003, while MERS was first detected in 2012. The outbreaks of SARS and MERS were not as widespread as the SARS-CoV-2, the virus that causes Covid-19, with far fewer US cases. They only gave a fraction of the deaths like Covid-19. However, they were both much more deadly.

Gottlieb’s comments on Wednesday follow recent studies that looked at immunity to a previous COVID infection compared to those who received the COVID vaccine.

A study in Israel found that the natural infection offered “more lasting and stronger protection” against the delta variant of the highly permeable coronavirus than Pfizer’s two-dose COVID vaccine. It has not yet been peer reviewed.

In contrast, a study in the UK, which has yet to be peer reviewed, came to a different conclusion. The researchers wrote: “The effectiveness of both doses is at least as great as the protection against a previous natural infection. Unlike the Israeli newspaper, participants in this study included two-dose vaccine recipients of AstraZeneca and Moderna in addition to Pfizer. were involved.

“I think overall it’s not clear if the vaccine-induced immunity is better, a little better, a little worse,” said Gottlieb, Natural Immunity.

Pfizer’s vaccine was fully approved last month by the FDA, which is still reviewing Moderna’s application for emergency use authorization in the United States for full approval. AstraZeneca has not received a single injection EUA in the United States from Johnson & Johnson, the only other vaccine administered in the United States approved for emergency use. J&J has yet to make the apple for full FDA approval.

Gottlieb acknowledged that the data shows a decline in vaccine safety over time. The United States is currently giving booster shots to people with weakened immune systems to counter it – and later this month, a larger portion of the population will be eligible for an additional dose of the vaccine.

“You can reintroduce a vaccine. You don’t want to reintroduce an infection, ”said Gottlieb, who led the FDA from 2017 to 2019 in the Trump administration. “To have infection-induced immunity you have to really get the infection, which we are actively trying to avoid, so there is a lot of merit in getting a vaccine in that regard.”

According to data compiled by the Centers for Disease Control and Prevention, about 62% of the U.S. population has received at least one dose of the COVID vaccine, while 52.4% have been fully immunized.

Health officials, politicians and business leaders are urging more Americans to get vaccinated against COVID. Many companies and other institutions such as universities are adopting strict policies on vaccine requirements, hoping to persuade those who are reluctant to get vaccinated.

Some illiterate Americans believe their previous coronavirus infections provide adequate protection against the disease, so they don’t feel the rush to get the vaccine. However, Gottlieb’s remarks on Wednesday add to his previously stated view that people already infected who are subsequently vaccinated have “the best of both worlds.”

“With at least one dose, you build broad, very deep, and very long-lasting immunity based on the data you’ve seen so far,” Gottlieb said July 6 on CNBC. “So there are still a lot of compelling reasons why you might want to get the vaccine, even if you’ve been infected before.”

Disclosure: Scott Gottlieb is a CNBC contributor and board member of Pfizer, genetic testing startup Tempus, health tech company Etion Inc., and biotech company. Illumina. He is also co-chair of Norwegian Cruise Line Holdings‘ And Royal Caribbeanof “Healthy Cells Panel”.



Please enter your comment!
Please enter your name here